Chemogenetic Synaptic Silencing of Neural Circuits Localizes a Hypothalamus→Midbrain Pathway for Feeding Behavior  by Stachniak, Tevye J. et al.
Neuron
NeuroResourceChemogenetic Synaptic Silencing of Neural
Circuits Localizes a Hypothalamus/Midbrain
Pathway for Feeding Behavior
Tevye J. Stachniak,1,2 Anirvan Ghosh,2,3 and Scott M. Sternson1,*
1Janelia Farm Research Campus, HHMI, 19700 Helix Drive, Ashburn, VA 20147, USA
2Neurobiology Section, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA
3Neuroscience Discovery and Translation Area, Pharma Research and Development, F. Hoffmann-La Roche, 4070 Basel, Switzerland
*Correspondence: sternsons@janelia.hhmi.org
http://dx.doi.org/10.1016/j.neuron.2014.04.008SUMMARY
Brain function is mediated by neural circuit connec-
tivity, and elucidating the role of connections is aided
by techniques to block their output. We developed
cell-type-selective, reversible synaptic inhibition
tools for mammalian neural circuits by leveraging G
protein signaling pathways to suppress synaptic
vesicle release. Here, we find that the pharmacolog-
ically selective designer Gi-protein-coupled receptor
hM4D is a presynaptic silencer in the presence of its
cognate ligand clozapine-N-oxide (CNO). Activation
of hM4D signaling sharply reduced synaptic release
probability and synaptic current amplitude. To
demonstrate the utility of this tool for neural circuit
perturbations, we developed an axon-selective
hM4D-neurexin variant and used spatially targeted
intracranial CNO injections to localize circuit connec-
tions from the hypothalamus to the midbrain respon-
sible for feeding behavior. This synaptic silencing
approach is broadly applicable for cell-type-specific
and axon projection-selective functional analysis of
diverse neural circuits.
INTRODUCTION
Rapid, reversible, and cell-type-specific blockade of synaptic
communication between neurons is important for assessing
the function of circuit connections. Several genetically encoded
tools have been developed for inhibiting synaptic vesicle release.
For example, temperature-sensitive impairment of synaptic
transmission with shibirets, a dynamin allele, has been widely
used in Drosophila behavioral studies to provide rapid and
reversible inhibition of genetically defined circuits (Kitamoto,
2002). Likewise, blockade of synaptic transmission with tetanus
toxin light chain has been refined to allow inducible blockade,
albeit over slow timescales of days to weeks, through doxycy-
line-dependent control of tetanus toxin light chain expression
(Yamamoto et al., 2003). However, neither of thesemethods pro-
vides a means to spatially restrict synaptic inhibition to just asubset of neuronal projections originating from a cell type.
MIST is a chemogenetic method for inactivating synaptic release
in the presence of a small molecule, but it requires considerable
overexpression to overcome endogenous synaptic release
machinery (Karpova et al., 2005). InSynC, an optogenetic
method, reduces evoked synaptic release in the presence of
blue light by chromophore-assisted light inactivation of synaptic
vesicle proteins, but this is accompanied by an undesirable rise
in spontaneous neurotransmitter release (Lin et al., 2013). Other
cell-type-specific methods for blocking circuit connections such
as optogenetic (Stuber et al., 2011; Tye et al., 2011) or chemoge-
netic (Magnus et al., 2011) silencing of axon projections are not
restricted to blocking local synaptic function and could also
block action potential transmission in axons expressing the
silencers that pass through the targeted site to more distal brain
regions, essentially analogous to a cell-type-selective ‘‘revers-
ible knife cut.’’
We considered pharmacological methods to achieve rapid,
reversible, selective, and localized control over synaptic vesicle
release. Metabotropic signaling from Gi-coupled receptors, for
example, GABAB receptors or opioid receptors, are well estab-
lished to suppress synaptic vesicle release (Heinke et al., 2011;
Takahashi et al., 1998). Multiple mechanisms appear to be
involved (de Jong and Verhage, 2009; Dittman and Regehr,
1996), including calcium channel suppression (Hescheler et al.,
1987; Takahashi et al., 1998) and interference with the synaptic
vesicle fusion machinery (Blackmer et al., 2001; Photowala
et al., 2006). To achieve cell-type-specific metabotropic control
over similar pathways, we considered the possibility that a che-
mogenetic Gi-coupled signaling pathway would possess synap-
tic silencing activity that could be targeted using genetic
methods and activated pharmacologically. The designer recep-
tor hM4D is a modified version of the Gi-coupled human musca-
rinic receptor 4 that responds to the highly selective exogenous
ligand clozapine-N-oxide (CNO) and has been reported to inhibit
neuron electrical activity (Armbruster et al., 2007). In addition, the
native muscarinic 4 receptor is present in presynaptic terminals
(Rouse et al., 1998) and has been demonstrated to suppress
synaptic transmission (Dolezal and Tucek, 1998; Zhang et al.,
2002). Moreover, hM4D/CNO has been noted to reduce an
evoked synaptic current amplitude (Bock et al., 2013) and also
reduces spontaneous synaptic release frequency (Mahler
et al., 2014). However, neither of these studies determinedNeuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc. 797
Figure 1. hM4D Is a Synaptic Silencer
(A) In paired whole-cell patch-clamp recordings of an hM4D-expressing pre-
synaptic neuron (green) and an untransfected postsynaptic neuron (blue),
action potentials elicited by current injection (1.5 nA) in the presynaptic cell
produce excitatory synaptic currents in the postsynaptic partner.
(B) In the presence of the hM4D agonist CNO, the presynaptic action potential
is still elicited, but postsynaptic currents are inhibited.
(C) The average peak amplitude of the postsynaptic current (Base) is reduced
with CNO (n = 6).
(D) Failure rate increases with CNO, indicating a reduction in presynaptic
release probability (n = 6). Values are represented as means ± SEM. *p < 0.05,
***p < 0.001.
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release probability as opposed to the potential effects of hM4D
signaling on axonal excitability. Here, we show that hM4D and
an axon-selective variant are cell-type-specific and projection-
selective synaptic silencers when engaged by CNO and that
this activity is independent of the influence of hM4D on neuron
excitability. We also performed in vivo calibration for intracranial
microinjections of the ligand CNO for spatially precise suppres-
sion of circuit connections. We applied this tool for functional798 Neuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc.analysis of a hypothalamic feeding circuit, which enabled identi-
fication of a hypothalamus/midbrain feeding pathway.
RESULTS
hM4D Is a Synaptic Silencer
We assessed the synaptic silencing capabilities of hM4D in pairs
of synaptically connected layer 2/3 (L2/3) cortical neurons. Injec-
tion of depolarizing current triggered action potentials in hM4D-
expressing presynaptic neurons, which resulted in evoked
synaptic currents in their postsynaptic partners (Figure 1A).
The modest hyperpolarization of presynaptic hM4D-expressing
L2/3 neurons exposed to CNO (DVm, 2.5 ± 0.6 mV; 30 nM
CNO; p = 0.003 paired t test, n = 8; Figure S1A available online)
did not prevent action potential initiation in the presynaptic
neuron during current injection through the patch pipette. Appli-
cation of CNO reliably suppressed synaptic transmission (peak
current: 2.3 ± 0.9 pA; with 0.03–1 mM CNO: 0.7 ± 0.3 pA;
p = 0.03, paired t test, n = 6) (Figures 1B and 1C). Synaptic sup-
pression corresponded to an increased synaptic failure rate, i.e.,
the frequency with which a presynaptic action potential failed to
generate a postsynaptic current (failure rate, baseline: 60.0% ±
7.9%; CNO: 87.2% ± 4.1%; p < 0.001, paired t test, n = 6) (Fig-
ure 1D). Input resistance in the postsynaptic cell, which lacked
hM4D, was not significantly altered by exposure to CNO (base-
line: 286 ± 50 MU; CNO: 257 ± 35 MU; p = 0.2, paired t test,
n = 6). Therefore, the reduced amplitude of synaptic currents
and the increase in synaptic failure rate, which provides a direct
measure of presynaptic release probability (Dobrunz and
Stevens, 1997), demonstrates that hM4D signaling can robustly
inhibit synaptic neurotransmitter release.
We further investigated synaptic silencing with hM4D/CNO in
axonal projections from L2/3 to cortical layer 5 (L5). For this, we
coexpressed channelrhodopsin-2 (ChR2) in L2/3 neurons along
with hM4D using a Thosea asigna virus 2a (Donnelly et al., 2001)
ribosomal skip sequence (ChR2-2a-hM4D). This configuration
allowed us to use laser-scanning photostimulation to rapidly
probe connection properties of hM4D-expressing presynaptic
neurons. It was important to determine a photostimulation inten-
sity that overcame the modest hyperpolarization generated by
hM4D activation (DVm, 5.0 ± 0.7 mV; 1 mM CNO; p < 0.001,
paired t test versus baseline, n = 7), and action potentials in
L2/3 neurons could be reliably evokedwith perisomatic photosti-
mulation in the presence of 1 mM CNO (action potential fidelity,
baseline: 93.1% ± 3.3%; CNO: 92.7% ± 3.4%; p = 0.5, paired
t test, n = 11) or 10 mM CNO (action potential fidelity, baseline:
97.7% ± 1.7%; CNO: 94.8% ± 2.5%; p = 0.09, paired t test,
n = 12) (Figures 2A and 2C). Postsynaptic currents in L5 cortical
neurons were evoked by targeted photostimulation of L2/3
somata, and light-evoked synaptic currents were greatly
reduced (88%) with CNO (1 mM) (peak current, baseline: 19.1 ±
4.6 pA; CNO: 2.2 ± 0.5 pA; p = 0.004, paired t test, n = 7) (Fig-
ure 2B). This effect on synaptic transmission occurred within
minutes and washed out slowly, after which the synapse was
sensitive to resilencing by CNO (Figures S1B and S1C). The
IC50 for synaptic inhibition with CNO was 0.03 mM (Figure 2C),
similar to the reported dose response for CNO activation of the
related receptor hM3D (Armbruster et al., 2007). As expected
Figure 2. Efficacy and Potency of hM4D/
CNO Synaptic Silencing
(A) During loose-seal cell-attached recordings in
brain slices, pairs of photostimuli were targeted
with a focal laser spot (blue starburst) to ChR2/
hM4D-transfected L2/3 neurons, which evoked
action potentials from somata in L2/3. Application
of CNO (1 mM) does not substantially inhibit the
fidelity (action potential/photostimulus) of ChR2-
evoked action potential initiation.
(B) In whole-cell recordings from postsynaptic L5
neurons, CNO (1 mM) inhibits synaptic currents
evoked by photostimulation of presynaptic L2/3
neuron somata (n = 7) with two light pulses.
(C) CNO potently inhibits synaptic transmission
(red diamonds) but does not impair ChR2-induced
action potentials (purple squares).
(D) Paired-pulse photostimulation of ChR2/hM4D-
expressing L2/3 neurons (23 1ms, 20 Hz) showed
increased paired-pulse ratio (P2/P1) for evoked
synaptic currents in L5 neurons (30 nM, 100 nM,
and 1 mM CNO; n = 8, 6, and 7, respectively),
indicating that hM4D/CNO reduces presynaptic
release probability.
(E) Cell-attached recordings of back-propagating
action potentials elicited by photostimulation
of L2/3/L5 axons in L5 (blue starburst). L2/3
neurons coexpressed ChR2 and hM4D. Applica-
tion of CNO (1–10 mM) did not reduce the fidelity of
action potential back propagation (n = 8).
(F) In axon-attached recordings from the cut ends
of L2/3 neuron-transfected axons in L4 and L5,
axonal action potentials arising from L2/3 somatic
photostimulation were not impaired by hM4D/
CNO signaling, demonstrating that hM4D does not
suppress action potential propagation. Values
are represented as means ± SEM; n.s. p > 0.05,
*p < 0.05, **p < 0.01.
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tion in synaptic transmission was accompanied by an increased
paired-pulse ratio during exposure to several CNO concentra-
tions (Figure 2D). These experiments show that, for an afferent
axon projection pathway, hM4D/CNO is a potent, rapidly acting,
and reversible synaptic silencing system.
Because our aim was to develop a selective synaptic silencer
for neural circuits, we wanted to examine whether hM4D/
CNO might undesirably also act by suppressing action
potential propagation along axons. We determined that action
potential backpropagation was unaffected in L2/3/L5 axon
projections by photostimulation of axons in L5, which were still
detected at the somata of hM4D-expressing L2/3 neurons in
CNO (action potential fidelity, baseline 60.6% ± 12.2%;
1–10 mMCNO: 57.1% ± 12.1%; p = 0.2, paired t test, n = 8) (Fig-
ure 2E). In addition, loose-seal axon-attached recordings from
L2/3 neuron cut axons in layers 4 or 5 showed no significant
impairment of light-activated action potentials initiated at L2/3
somata (action potential fidelity, baseline: 86.5% ± 7.6%; CNO
1 mM: 84.6% ± 8.1%; p = 0.2, paired t test, n = 8) (Figure 2F).These experiments demonstrate that hM4D/CNO can selectively
silence synaptic transmission without blocking axonal action
potential propagation.
Suppression of Synaptic Release In Vivo
We next applied hM4D/CNO to inhibit synaptic release from a
molecularly defined circuit in vivo using intracranial microinjec-
tion of CNO to discrete brain areas. A critical consideration
was to identify the lowest efficacious dose of CNO for in vivo
microinjection, in order to optimize the spatial resolution of pro-
jection field silencing by avoiding hM4D activation at sites distant
from the targeted region due to spread of the agonist. Therefore,
we calibrated the CNO dose for synaptic inhibition bymonitoring
the behavioral output from a previously characterized (Atasoy
et al., 2012) hypothalamic circuit projection between
molecularly defined AGRP neurons in the hypothalamic arcuate
nucleus (ARC) and paraventricular hypothalamic (PVH) neurons
(ARCAGRP/PVH) (Figure S2A). Activation of AGRP neurons is
sufficient to rapidly elicit avid food intake (Aponte et al., 2011)
through axonal release of GABA and NPY in multiple brain areasNeuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc. 799
Figure 3. Spatially Targeted Synaptic
Silencing In Vivo
(A–C) Schematics for photostimulation of AGRP
neurons coexpressing ChR2 and hM4D in the
arcuate nucleus (ARC), while spatially targeting
CNO microinjection to the PVH. An angled optical
fiber is implanted over the ARC to photostimulate
AGRP neuron somata (green), which project axons
to multiple brain areas. AGRP neuron photo-
stimulation in this configuration robustly evoked
feeding (right). CNO or saline were targeted to the
PVH through an implanted cannula. (B) Focal
microinjection of CNO to the PVH during AGRP
neuron photoactivation result in selective silencing
of synaptic release from the targeted ARCAGRP/
PVH axonal projection field due to hM4D-medi-
ated synaptic inhibition. Evoked food intake is only
partially reduced because AGRP neuron axons
still transmit action potentials, and nontargeted
axon projections remain competent for synaptic
transmission. Injection sites were verified post-
mortem (inset) by injection of FluoroGold (blue)
and AGRP immunofluorescence (green). (C) In
some mice, cannula placement was outside of the
PVH by 300–500 mm (‘‘Miss’’).
(D) Local microinjections of CNO into the PVH
(‘‘Hits’’) significantly reduced feeding (3 mM CNO,
n = 5). No reduction in feeding was observed for
CNO injections that missed the PVH (3 mM CNO,
n = 4) or with CNO injections into ChR2-expressing
mice that lack hM4D (300 mM CNO, n = 5).
(E) PVHmicroinjection of CNO reduced feeding by
about 50% over a range of doses. Precision of
targeted synaptic silencing was reduced with
increasing CNO dose, as evidenced by the
capacity of injections that miss the PVH to inhibit
feeding. Intraperitoneal injection of CNO further
reduced evoked feeding to basal levels (18%± 4%
of evoked feeding). Values are represented as
means ± SEM. *p < 0.05.
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blocking GABA or NPY receptor signaling in the PVH during
AGRP neuron activation found that blockade of this circuit
suppresses evoked feeding by 50% (Atasoy et al., 2012).
Therefore, we used hM4D/CNO to inhibit synaptic release from
ARCAGRP/PVH axons, which allowed us to use the reduction
of evoked food consumption as a readout for the efficacy of
in vivo cell-type-specific synaptic silencing.
To selectively block ARCAGRP/PVH circuits with hM4D/CNO,
we first determined ex vivo that hM4D signaling robustly sup-
pressed ChR2-evoked synaptic transmission in ARCAGRP/
PVH circuits, which was reduced by 84% (peak current, base-
line: 12.1 ± 3.2 pA; CNO: 1.9 ± 0.6 pA; p = 0.01, paired t test,
n = 5) (Figure S2B). As demonstrated previously (Krashes
et al., 2011), hM4D also decreased spontaneous firing in AGRP
neurons (baseline firing rate: 1.91 ± 0.51 Hz; 1 mM CNO: 0.77 ±
0.48 Hz; p = 0.04, paired t test, n = 7); however, light-evoked
action potential fidelity in ChR2/hM4D coexpressing AGRP neu-
rons was not significantly reduced in the presence of CNO (base-
line: 97.6% ± 1.7%; CNO 1 mM: 92.4% ± 4.6%; p = 0.1, paired
t test, n = 7). For in vivo analysis, mice coexpressing ChR2 and800 Neuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc.hM4D in AGRP neurons were implanted with an optical fiber
positioned to evoke feeding by photostimulating AGRP somata
in the ARC (1 hr), along with a microinjection cannula above
the PVH (Figure 3A). Intracranial microinjection of CNO (3 mM,
50–100 nl) in the PVH reduced feeding by 50% during AGRP
neuron photostimulation (PVH saline: 0.65 ± 0.17 g; PVH CNO:
0.32 ± 0.04 g; p = 0.01, paired t test, n = 5) (Figures 3B and
3D), similar to previous results using pharmacological blockade
of GABA receptors andNPY1R in the PVH (Atasoy et al., 2012). In
control animals transfected with ChR2 but not hM4D, CNO injec-
tion to the PVH did not reduce evoked feeding even at the high-
est CNO doses tested (PVH saline: 0.91 ± 0.13 g; CNO 300 mM:
0.84 ± 0.07 g; p = 0.2, paired t test, n = 5) (Figure 3D). Further-
more, synaptic inhibition with CNO was spatially localized to
the PVH, because microinjections that missed the PVH by
300–500 mm (3 mM CNO, 50–100 nl) did not impair AGRP
neuron-evoked feeding (saline: 0.46 ± 0.03 g; CNO: 0.52 ±
0.10 g; p = 0.3, paired t test, n = 4) (Figures 3C and 3D). At higher
CNO doses, feeding suppression did occur with the mistargeted
microinjections, indicating substantially reduced precision (Fig-
ure 3E). Thus by establishing an in vivo dose response
Figure 4. Axon Projection-Selective Silencing with hM4Dnrxn
(A) hM4Dnrxn was constructed by addition of an intracellular amino acid sequence from neurexin-1 (aa 1,4251,479) to the C terminus of hM4D that also contained
a C-terminal hemagglutinin (HA) tag.
(B) Cell surface distribution of N-terminal (extracellular) epitope-tagged HA-hM4D (Armbruster et al., 2007) and HA-hM4Dnrxn (see Experimental Procedures) was
determined in hippocampal neuronal cultures that were cotransfected with EGFP. For surface labeling, anti-HA immunofluorescence was measured without
membrane permeabilization. HA-hM4Dnrxn showed reduced intensity in the somatic compartment but not the axonal compartment, compared to HA-hM4D.
Label intensity was quantified using linescans (hashed lines) across the cell body or synaptic boutons. EGFP fluorescence (HA/EGFP overlay) was used to trace
axons and identify transfected neurons. Representative soma and axon images of anti-HA immunofluorescence were adjusted identically for brightness and
contrast for display purposes. Cells transfected with EGFP alone did not show detectable signal for surface label anti-HA immunofluorescence.
(C) The surface expression of HA-hM4Dnrxn is distributed to the axonal compartment, as illustrated by a reduction in soma:axon (S/A) immunofluorescence ratio,
relative to HA-hM4D.
(D) In cortical brain slices coexpressing hM4Dnrxn and ChR2, synaptic inhibition of L2/3/L5 transmission is as effective with hM4Dnrxn (n = 5) aswith hM4D (n = 8).
(E) The dose response relationship for synaptic inhibition with CNO is similar for hM4Dnrxn and hM4D.
(F) Hyperpolarization in L2/3 cortical neurons expressing hM4Dnrxn was negligible with CNO (1 mM) (n = 6).
(G) Conductance change in response to CNO (1 mM) is markedly reduced in L2/3 cortical neurons expressing hM4Dnrxn (n = 6), as compared to hM4D (n = 7).
Values are represented as means ± SEM; n.s. p > 0.05, **p < 0.01, ***p < 0.001.
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projections, we identified 3 mM CNO as sufficient to induce
maximal suppression of this circuit (Figure 3E) with a precision
of ±500 mm. hM4D-mediated synaptic inhibition is therefore an
efficacious and selective means of performing functional in vivo
analysis of spatially defined axon projections from molecularly
defined neuron populations.
Selective Synaptic Silencing with hM4D Axonal
Targeting
In light of the dual properties of hM4D/CNO as a silencer of
neuron electrical activity and synaptic vesicle release, we further
refined hM4D for selective synaptic silencing by engineering an
axon-selective variant. Preferential axonal distribution of mem-
brane proteins has been accomplished by addition of amino
acid sequences that bind myosin motors, which preferentiallyshuttle surface proteins into axons (Lewis et al., 2011). Alterna-
tively, amembrane proteinmay be delivered to both somatoden-
dritic and axonal compartments and then actively removed from
the surface at the cell body by selective somatodendritic endo-
cytosis, as has been shown for a member of the neurexin super-
family (Bel et al., 2009). Because the native humanM4 receptor is
already present at presynaptic terminals (Rouse et al., 1998), we
chose to reduce somatic surface expression of hM4D, while
maintaining axonal distribution, with the C-terminal addition of
the intracellular sequence of neurexin 1a (Fairless et al., 2008;
Kim et al., 2012) and a 23 hemagglutinin (HA) tag, resulting in
the modified receptor hM4Dnrxn (Figure 4A).
To examine whether the subcellular distribution of hM4Dnrxn at
the extracellular membrane surface is biased to axons, we also
developed N-terminal-tagged hM4D variants with extracellular
presentation of an HA epitope. Cell surface labeling of HA-hM4DNeuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc. 801
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Chemogenetic Synaptic Silencingand HA-hM4Dnrxn (see Experimental Procedures) revealed
reduced HA-hM4Dnrxn somatic expression, but axonal expres-
sion was maintained, which resulted in a reduced somatic:axo-
nal (S/A) distribution for this receptor (S/A ratio, HA-hM4D:
0.88 ± 0.07; HA-hM4Dnrxn: 0.23 ± 0.03; p < 0.001, two-sample
t test assuming unequal variance, n = 5 and 6, respectively) (Fig-
ures 4B and 4C). Synaptic silencing of L2/3/L5 projections with
hM4Dnrxn is robust (synaptic inhibition at 1 mM CNO: 92.6% ±
5.5%; n = 5) (Figures 4D and 4E). However, consistent with its
largely axonal subcellular distribution, hM4Dnrxn activation in
L2/3 cortical neurons with CNO lacks significant somatic hyper-
polarization (Vm, baseline: 66.0 ± 2.3 mV; 1 mM CNO: 66.3 ±
2.2 mV; p = 0.3, paired t test, n = 6) (Figure 4F) and also lacks the
somatic conductance increase seen with hM4D activation (DGin
at 1 mMCNO, hM4D: 23.0%± 6.1%; hM4Dnrxn: 2.2%± 1.4%; p =
0.007, two-sample t test assuming unequal variance, n = 7 and 6,
respectively) (Figure 4G). This optimized tool allows selective
and potent (Figure 4E) synaptic silencing with negligible effects
on neuron excitability.
Selective Synaptic Silencing to Functionally Map a
Hypothalamus/Brainstem Feeding Circuit In Vivo
To test the in vivo efficacy of the axon-selective synaptic
silencing receptor, we applied hM4Dnrxn to functionally decon-
struct an additional circuit node that regulates appetite. AGRP
neuron activation results in feeding behavior, in part, by inhibition
of PVH neurons, and, consistent with this, PVH neuron chemo-
genetic silencing with hM4D/CNO is sufficient to evoke food
consumption (Figure S2A). Classic studies that used knife cuts
and asymmetric ‘‘dual-disconnection’’ lesioning to produce
overeating concluded that this behavior involved axon projec-
tions from PVH neurons to the nucleus of the solitary tract and
dorsal vagal complex (NTS/DVC) in the hindbrain (Kirchgessner
and Sclafani, 1988; McCabe et al., 1984). To further investigate
the circuit node downstream of the PVH that is sufficient to elicit
voracious food intake during loss-of-function manipulations, we
sought to use cell-type-specific synaptic silencing of spatially
defined PVH axon projections.
PVH neurons were selectively targeted in Sim1-Cre mice (a
line with Cre-recombinase expression in the PVH) (Balthasar
et al., 2005) by transduction with a Cre-dependent virus coex-
pressing hM4Dnrxn and the fluorescent protein mCherry. As with
cortical neurons, activation of hM4Dnrxn with CNO in these
PVHSIM1 neurons did not increase conductance, while hM4D/
CNO did (DGin at 1 mM CNO, hM4D: 24.8% ± 6.3%; hM4D
nrxn:
1.6% ± 0.9%; p = 0.007, two-sample t test assuming unequal
variance, n = 6 and 8, respectively). As an initial test of efficacy,
we confirmed that systemic CNO injection in mice with
hM4Dnrxn in PVHSIM1 neurons, which should inhibit synaptic
release from all of the axon projection fields of PVH neurons,
was sufficient to evoke feeding (baseline feeding, 1 hr: 0.07 ±
0.01 g; CNO, 1 hr: 0.58 ± 0.02 g; n = 32). To functionally map
PVHSIM1 axon projection fields that are involved in this hyper-
phagic behavior, we targeted intracranial CNO injections to
PVHSIM1 axon projections in the hindbrain (Figures 5A and
S3A). We first examined PVHSIM1/NTS/DVC projections with
bilateral delivery of CNO to the NTS/DVC in mice with hM4Dnrxn
in PVHSIM1 neurons. This manipulation failed to significantly802 Neuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc.increase food intake, even with high dose CNO injections
(baseline feeding, 1 hr: 0.07 ± 0.03 g; CNO 3, 300 mM: 0.1 ±
0.03 g; p = 0.3, paired t test, n = 9) (Figure 5B, far right). This
was contrary to expectations based on knife cut and lesion
experiments (Kirchgessner and Sclafani, 1988; McCabe et al.,
1984), so we considered the possibility that a key excitatory
serotonergic projection from raphe magnus/obscurus/NTS
(Wu et al., 2012) may also have been lesioned in prior knife
cut experiments but not in our cell-type-selective synaptic
silencing experiments. NTS injection of the serotonin receptor
3 antagonist ondansetron has been used to block this circuit
connection (Wu et al., 2012). However, hM4Dnrxn/CNO synaptic
inhibition of PVHSIM1/NTS/DVC in the presence of ondanse-
tron (2 mM) was also insufficient to recapitulate the effects of
systemic PVHSIM1 neuron silencing (baseline feeding, 1 hr:
0.12 ± 0.04 g; CNO 3, 30, or 300 mM: 0.06 ± 0.03 g; p = 0.2,
paired t test, n = 6). Therefore, inhibition of PVHSIM1/NTS/
DVC axon projections is not sufficient to acutely elicit food
consumption under these conditions.
To locate the circuit node responsible for feeding behavior
during PVH neuron inhibition, we next used hM4Dnrxn/CNO to
suppress synaptic release at several other hindbrain and
midbrain sites targeted by PVHSIM1 axon projections. Based
on in vivo dose response experiments in the ARCAGRP/PVH
circuit (Figure 3E), we used microinjection of 3 mM CNO to
inhibit synaptic interactions at four additional positions along
the neuraxis, which also included a range of sites along the
transverse axis (Figure 5A). Under these conditions, we
observed a functional ‘‘hotspot’’ that evoked feeding behavior
during synaptic silencing of PVHSIM1 axons in the region of
the caudal ventrolateral periaqueductal gray (PAGvl) and the
dorsal raphe complex (DR) (baseline feeding, 1 hr: 0.09 ± 0.03
g; CNO: 0.49 ± 0.06 g, p < 0.001, paired t test, n = 10) (Figures
5B and 5C). Injections at more rostral locations were less effec-
tive at eliciting food intake with 3 mM CNO (Figures 5B and 5C;
also see Figure S3B), further indicating that these behavioral ef-
fects of hM4Dnrxn activation were not due to inhibition of action
potential transmission in axons of passage in vivo. Microinjec-
tions targeted to adjacent, caudal PVHSIM1 axon projections in
the vicinity of the locus coeruleus and parabrachial nucleus
only occasionally evoked feeding with 3 mM CNO (Figures 5B
and 5C), typically requiring higher CNO concentrations (Fig-
ure 5D). Some midbrain and hindbrain intracranial micro-
injections had a trajectory that passed through a portion of
the fourth cerebral ventricle, and injections targeted directly to
either the cerebral aqueduct or the fourth ventricle could also
evoke feeding in several cases (Figures S3Bi and S3Bii). How-
ever, this is not likely to be the cause of evoked feeding found
for injections targeting the PAGvl/DR hotspot because (1)
caudal injection sites usually exhibited extensive penetration
of the fourth ventricle (sites in Figure 5C, far right), but none
of these evoked food intake with 3 mM CNO; and (2) feeding
could be elicited by intracranial injection of CNO (3 mM) around
the PAGvl that did not damage the fourth ventricle (Figures
S3Biii and S3Biv). Taken together, experiments using
hM4Dnrxn/CNO for chemogenetic synaptic silencing identified
the PAGvl/DR area as a key node downstream of the PVH
that mediates feeding behavior.
Figure 5. Cell-Type-Selective Synaptic Silencing Localizes a Feeding Circuit
(A) Schematic of descending axon projections from PVHSIM1 neurons, which express hM4Dnrxn. These axon projections were targeted in separate animals for
spatially defined synaptic silencing by intracranial microinjection of CNO. Estimated precision of microinjections (based on ±500 mm) at each site is indicated
by colored circles (for clarity, cannula schematic is not shown for ‘‘purple’’ injection site). Injection cannula was angled for PAG targeting in order to avoid the
sinus confluens (blood vessel, dark red).
(B) Preinjection baseline (Base) and evoked feeding response (1 hr) from regions targeted by intracranial injections (CNO, 3 mM, typically bilateral) at distinct
anterior-posterior positions. The most efficacious feeding responses were observed with microinjections into the PAGvl/DR (light green), which was similar to
food consumption evoked by intraperitoneal injection of CNO (IP). Intracranial microinjections that were more ventral or dorsal than the indicated areas were not
included in the analysis.
(C) Schematic of sagittal section showing the location of injection sites, which are color coded to reflect food intake evoked after intracranial 3 mM CNO
microinjection, normalized to feeding after IP injection. Two transverse sections are displayed, at the level of PAGvl/DR and the caudal PBN, with the positions of
multiple injection sites projected onto a coronal diagram. Bilateral injections are displayed as identically color-coded pairs. Asterisks denote bilateral microin-
jection site at the pedunculopontine tegmental nucleus (PPTg), which did not evoke substantial food intake.
(D) Dose response for CNOmicroinjections at different injection sites. Selectivity is reduced with increasing CNO dose, such that microinjection sites outside the
PAGvl/DR region can evoke feeding. Values are represented as means ± SEM.
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Table 1. Cell-Type-Specific Techniques for Silencing Axon Projections
Tool Timescale Mechanism Limitations
NpHR/Arch Millisecond to minutes Inhibits action potential Axons-of-passage also silenced
PSAM-GlyR Minutes to 1 hr Inhibits action potential Axons-of-passage also silenced; intracranial microinjection
MIST Minutes to hours Inhibits transmitter release Requires high expression level; intracranial microinjection
InSynC Minutes to 1 day Inhibits transmitter release Increases spontaneous neurotransmitter release
hM4Dnrxn Minutes to hours Inhibits transmitter release Intracranial microinjection
Neuron
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Chemogenetic Synaptic Silencing
Here, we describe a method to cell-type specifically silence
neural circuit connections by inhibiting synaptic neurotrans-
mitter release probability. hM4Dnrxn/CNO strongly suppresses
neuronal output through synaptic inhibition without somatic
hyperpolarization. Selective synaptic inhibition complements
optogenetic (Stuber et al., 2011; Tye et al., 2011) or chemoge-
netic (Magnus et al., 2011) axonal silencing techniques, which
can also block action potential transmission through axons of
passage that target more distal brain areas. Therefore, selective
synaptic silencing can enable a more precise localization of
critical neural circuit interactions. Using ARCAGRP/PVH, a pre-
viously characterized hypothalamic circuit interaction, to cali-
brate the in vivo dosing of CNO, we found that intracranial
microinjection of 3 mM CNO is suitable for inhibiting synaptic
interactions within ±500 mm of the injection site (Figure 3B).
This calibration experiment was critical for determining the res-
olution for this system at an efficacious dose, and it also indi-
cates better resolution here than a recent application of
hM4D for projection silencing using microinjections of 1 mM
CNO (Mahler et al., 2014). We also found a corresponding
in vivo dose response relationship for CNO in synaptic silencing
experiments with the axon-targeted variant hM4Dnrxn for the
circuit PVHSIM1/PAGvl/DR (Figure 5D), supporting the use of
3 mM CNO for intracranial microinjections. The precision of
in vivo synaptic silencing for PVHSIM1/PAGvl/DR could be
further enhanced by tiling a region of interest with targeted
CNO microinjections as demonstrated by the sharp hotspot
we observed for evoked feeding behavior with microinjections
at the midbrain/hindbrain boundary (Figures 5B and 5C). These
results show that acute chemogenetic synaptic silencing can
be used to localize circuit interactions that have a causal role
for mouse behavior.
Using hM4Dnrxn/CNO, spatially defined synaptic output of
molecularly defined neuron populations can be rapidly and
selectively blocked, allowing the behavioral influence of a partic-
ular projection field to be examined. This approach offers an
alternative to the commonly used method of pharmacological
blockade of postsynaptic receptors, which undesirably impairs
communication through other pathways and perturbs neuronal
activity. Cell-type-selective hM4D/CNO synaptic silencing of
the ARCAGRP/PVH axonal release sites during exogenous
AGRP neuron photostimulation tested the necessity of a specific
projection field for feeding behavior and avoided unwanted alter-
ation of baseline postsynaptic neuron activity. In addition, cell-
type-selective synaptic silencing under endogenous neuronal804 Neuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc.activity patterns also can be used to functionally map behavior-
ally important circuit connections, which we applied to identify
suppression of the PVHSIM1/PAGvl/DR circuit connection as
sufficient to induce overeating behavior.
Technical Considerations
Multiple methods are available for rapid, cell-type-specific and
axon projection-selective inhibition of circuit function (Table 1).
For rapid timescale silencing, optogenetic tools such as NpHR
or Arch are necessary; however, for long-term projection
silencing, these tools may require delivery of considerable en-
ergy into the brain. Optogenetic destruction of synaptic vesicle
fusion machinery (InSynC) appears selective for silencing
evoked release from specific synaptic targets, but this technique
requires consideration of undesired elevated tonic spontaneous
synaptic vesicle release (Lin et al., 2013). Our experiments indi-
cate that chemogenetic silencing in vivo with hM4D or hM4Dnrxn
and CNO robustly silences synaptic release within minutes,
without significantly reducing axonal action potential propaga-
tion, and this reverses within 1–4 hr. In contrast, optogenetic
activation of chloride or proton pumps (e.g., NpHR or Arch)
(Jennings et al., 2013; Stuber et al., 2011) or the chemogenetic
silencing tool PSAM-GlyR (Magnus et al., 2011) probably sup-
presses circuit connections by blocking action potential propa-
gation (Tye et al., 2011), which, depending on axonal anatomy,
can also influence axons of passage projecting to more distal
brain areas. In our synaptic silencing experiments with
PVHSIM1/PAGvl/DR, we found that more rostral sites contain-
ing PVH axons were less effective at inducing overeating (Fig-
ures 5B and 5C), indicating that action potential propagation
was not blocked. Therefore, synaptic silencing with hM4Dnrxn
is well suited to disentangle the relative contribution of inter-
mingled, molecularly defined axon projections at specific synap-
tic targets over timescales of minutes to hours.
The major limitation for using hM4Dnrxn to selectively silence
synaptic projections involves the requirement to intracranially
administer a CNO-containing solution. Pressure injections,
which were used here, can diffuse and reduce resolution. In
addition, pressure injections are not well suited to in vivo electro-
physiological recordings due to tissue movement. An additional
issue with intracranial microinjection is that it often requires
perturbation of the animal’s behavior during CNO infusion into
the brain, which is unsuitable for some behavioral experiments.
Finally, intracranial injections require consideration of the
possible access of CNO into the ventricular system. In our exper-
iments, this was potentially an issue; however, many of the injec-
tions following trajectories that passed through the fourth
ventricle did not affect feeding, and some microinjections to
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not penetrate the fourth ventricle (Figure S3Biii). Because intra-
cranial microinjections are widely used in behavioral studies,
these considerations are well appreciated as are appropriate
control experiments (as in Figure S3B).
Synaptic Silencing for Mapping a Feeding Circuit in the
Mouse Brain
Our investigation of the circuits through which suppression of
PVH neuron activity elicits feeding behavior was unable to
confirm the prediction of classical lesion and knife cut experi-
ments, which concluded that hyperphagia fromPVH loss of func-
tion was mediated by a PVH/NTS/DVC circuit projection.
Instead,we found that synaptic silencingof PVHSIM1 axonprojec-
tions to the PAGvl/DR region elicited feeding. It is unlikely that the
behavioral response resulted fromspread ofCNO tomore caudal
PVHSIM1 axonal release sites, suchas thePBNor the locus coeru-
leus (Figure S3A), because direct injections into these areas did
not elicit food intake with 3 mM CNO. PVHSIM1 axon projections
to the pedunculopontine tegmental nucleus (PPTg) (Figure S3A)
are also less likely to be directly responsible for feeding in these
experiments, because direct targeting with 3 mM CNO failed to
elicit feeding (asterisk in Figure 5C). Another nearby brain area,
the lateral dorsal tegmental area (LDTg), had few PVHSIM1 axons
(Figure S3A). Therefore, using the hM4Dnrxn/CNO synaptic
silencingmethod indicates a PVHSIM1/PAGvl/DR circuit that re-
strains appetite and is sufficient to mediate rapid food intake
associated with PVH neuron inhibition, for example, by intero-
ceptive AGRP neurons that read out circulating signals of bodily
energy status (ARCAGRP/PVHSIM1/PAGvl/DR).
The circuit interaction from PVH to PAGvl/DR has been
described anatomically (Geerling et al., 2010; Zheng et al.,
1995), but the functional properties are not understood. Many
PVH neurons express the vesicular glutamate transporter 2
(Slc17a6), but few PVH neurons express vesicular GABA trans-
porter (Figure S3D). Furthermore, genetic deletion of Slc17a6
from the PVH can lead to hyperphagia (Xu et al., 2013), indicating
that PVHSIM1/PAGvl/DR may be an excitatory circuit that sup-
presses appetite, and loss of function evokes feeding. Addition-
ally, multiple neuropeptides present in different PVH populations
could also influence the functional characteristics of this circuit.
Although the role of the PAGvl to elicit feeding behavior is mostly
unexamined, refeeding after food deprivation is suppressed by
PAG microinjections of the neuropepide bombesin (Kyrkouli
et al., 1987), and feeding during lateral hypothalamus electrical
stimulation is inhibited by morphine in the PAGvl (Jenck et al.,
1987). The DR has been implicated in feeding behavior using
electrolytic lesions (Fletcher and Coscina, 1993) as well as inac-
tivation of the DR with muscimol (Klitenick and Wirtshafter,
1988), both of which increased feeding in rats. DR is a major
source of brain serotonin, which is a pathway targeted in clinical
approaches to reduce food intake and body weight (Halford
et al., 2011). The experiments reported here prioritize PAGvl
and DR for more detailed analysis of the relative contribution of
the component cell types downstream of PVHSIM1 neurons that
control food intake.
Our experiments that did not find evidence for acute feeding
control from silencing circuit connections from PVHSIM1/NTS/DVC contrast with conclusions drawn from classical dual asym-
metric lesion experiments. Those studies found that unilateral
lesions of PVH and contralaterally positioned knife cuts around
the NTS increased feeding dramatically, indicating a role for the
NTS/DVC in PVHSIM1-evoked feeding (Kirchgessner and Sclafani,
1988). Inaddition,PVH injectionofnoradrenaline results in feeding,
and this was blocked with knife cuts in PAG, PBN, and ventral
medulla, corresponding to the trajectory of descendingPVH fibers
(McCabe et al., 1984; Weiss and Leibowitz, 1985). Together with
our experiments indicating a key PVHSIM1/PAGvl/DR circuit,
these results might reflect the possibility that caudal hindbrain
knife cuts sever a further descending circuit originating from
PAGvl/DR to regions in the vicinity of the NTS. Alternatively,
because knife cuts and lesions do not distinguish ascending and
descending axons, these manipulations might also have cut an
ascending appetite suppression circuit (see, for example NTS/
PBN [Wuet al., 2012]), which in concertwith a unilateral PVH lesion
could result in a feeding response. The complexity associatedwith
interpretation of nonselective lesion methods for circuit functional
analysis further highlights the usefulness of the genetically
encoded, pharmacologically selective, and synapse-specific
manipulations enabled by hM4Dnrxn/CNO silencing.
EXPERIMENTAL PROCEDURES
All experimental protocols were conducted according to U.S. National Insti-
tutes of Health guidelines for animal research and were approved by the Insti-
tutional Animal Care and Use Committee at Janelia Farm Research Campus.
Mice
Animals were housed on a 12 hr light (06:00)/dark (18:00) cycle with ad libitum
access to water and mouse chow (PicoLab Rodent Diet 20, 5053 tablet,
TestDiet), unless otherwise noted. Agrp-IRES-Cre (Tong et al., 2008) and
Sim1-Cre (Balthasar et al., 2005) mice have been described previously. For
characterizing in vivo and ex vivo dose responses, both male and female
micewere used in cortical brain slice physiology (11–17 days old), hypothalam-
ic brain slice physiology (6–10 weeks old), and photostimulation (6–10 weeks
old) experiments (Figures 1, 2, and 3). Most mice in PVHSIM1 circuit mapping
experiments (Figure 5)weremale (49/51 animals). For in utero electroporations,
timed pregnant female C57Bl/6NCrl mice were purchased from Charles River
Laboratories and neurons in embryonic day 15.5 embryos were electroporated
following pressure microinjection (Picospritzer) into the right lateral ventricle of
a DNA mixture (0.5 mg/ml, approximately 200 nl), encoding the channel or re-
ceptor of interest and an EGFP marker. For all animal surgeries, postoperative
analgesia was provided. Buprenorphine was administered intraperitoneally
(0.1 mg/kg) along with ketoprofen administered subcutaneously (5 mg/kg).
Viral Vectors
rAAV2/1-CAG-FLEX-rev-ChR2tdTomato, rAAV-CAG-FLEX-rev-hM4D-2a-
EGFP, and rAAV-CAG-FLEX-rev-PSAML141F-GlyR were described previ-
ously (Atasoy et al., 2008, 2012; Magnus et al., 2011). The rAAV2/9-CAG-
FLEX-rev-ChR2-2a-hM4D vector was prepared by ligating ChR2 and
hM4D with an intervening DNA fragment encoding a T2a amino acid
sequence from Thosea asigna virus (EGRGSLLTCGDVEENPGP) (Donnelly
et al., 2001), inserted into the rAAV2-CAG-FLEX backbone in an inverted
orientation. Codon-optimized hM4Dnrxn (DNA 2.0) was constructed from
hM4D with a C-terminal 23 HA tag and followed by the intracellular domain
of neurexin-1a (aa 1,425–1,479). rAAV2/9-CAG-FLEX-rev-mCherry-
2a-hM4Dnrxn was prepared by ligating mCherry and hM4Dnrxn with an
intervening DNA fragment encoding a T2a amino acid sequence
(EGRGSLLTCGDVEENPGP) and insertion into the rAAV2-CAG-FLEX back-
bone in an inverted orientation. Viral vectors were produced by the University
of Pennsylvania Gene Therapy Program Vector Core or the Janelia FarmNeuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc. 805
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able at http://www.addgene.org/Scott_Sternson/.
Viral Injections, Fiber, and Cannula Placement
Viral injections were performed as described previously (Atasoy et al., 2008)
(postnatal days 21–25 [P21–P25] for electrophysiological recordings, P40–
P50 for behavioral experiments). For AGRP neuron somatic activation in
the ARC in conjunction with ARCAGRP/PVH synaptic inhibition, adult male
and female Agrp-IRES-Cre animals were unilaterally transduced in the
arcuate nucleus with rAAV2/9-CAG-FLEX-rev-ChR2-2a-hM4D or in a few
cases rAAV-CAG-FLEX-rev-hM4D-2a-EGFP plus rAAV2/10-CAG-FLEX-rev-
ChR2tdtomato (400 nl per side). ARC coordinates were the following:
bregma 1.45 mm, midline +0.15 and +0.25 mm; dorsal surface 6.05 mm
and 5.95 mm. For photostimulation experiments, a guide cannula was
inserted ipsilaterally into thePVH (bregma0.7mm,midline0.2mm,dorsal sur-
face3.5mm, 26GA) and a ferrule-capped optical fiberwas placed at an angle
to target the ARC over the ChR2-transduced AGRP neurons (bregma 2.9,
midline 0.15 mm, dorsal surface 4.65 mm, angled 13 toward anterior).
CNO injection into AGRP neuron photostimulation control subjects lacking
hM4Dwere Agrp-IRES-Cre;Ai32 (Madisen et al., 2010) and Agrp-IRES-Cre an-
imals unilaterally transduced in the arcuate nucleus with rAAV-CAG-FLEX-rev-
PSAML141F-GlyR plus rAAV2/10-CAG-FLEX-rev-ChR2-tdtomato for 20 weeks.
HigherAGRPneuronChR2penetranceandexpression levelsprobably account
for the increased evoked feeding observed in these animals relative to ChR2-
2a-hM4D animals, which were used 4-6 weeks after rAAV injection.
For synaptic silencing of PVH axon projections, adult Sim1-Cre animals were
bilaterally transduced in the PVH with rAAV2/9-CAG-FLEX-rev-mCherry-
2a-hM4Dnrxn or in a few cases rAAV-CAG-FLEX-rev-hM4D-2a-EGFP (300 nl
per side). PVH coordinates were the following: bregma 0.7 mm;
midline ±0.25 mm; dorsal surface 4.9 mm, 4.7 mm, and 4.5 mm. Animals
well infected with either hM4D or hM4Dnrxn reliably produced feeding after 2.5–
3 weeks of expression. In mice that ate at least 0.4 g/hr in response to i.p.
CNO, bilateral cannulas (26 GA) were then placed at various rostral-caudal posi-
tions, varying in lateral separation tomatch the trajectory ofPVHSIM1axonprojec-
tions. Cannula position coordinates were the following: NTS/DVC cannula
(bregma 7.2 mm, midline ±0.25 mm or ±0.5 mm, dorsal surface 4.2 mm);
PBN cannula (bregma 5.8 mm, midline ±1 mm or ±1.5 mm, dorsal
surface 3.7 mm); LC cannula (bregma 5.8 mm, midline ±0.25 mm
or±0.5mm,dorsalsurface3.7mm,angled10 towardanterior);PAGvl/DRcan-
nula (bregma5.6 mm,midline ±0.25mmor ±0.5mm, dorsal surface3.5 mm,
angled 10–14 toward anterior); PAG anterior (bregma 2.9 mm,
midline ±0.5 mm, dorsal surface 3.2 mm, angled 0–25 toward posterior);
cerebral aqueduct (bregma 2.9 mm, midline 0 mm, dorsal surface 3.2 mm,
angled 10–12 toward posterior); fourth ventricle (bregma 5.8 mm, midline
0mm, dorsal surface3.7mm). Injections targeting PAGweremade at an angle
to avoid rupturing the vasculature at the confluence of the superior sagittal sinus
and transverse sinus (bregma 3.1 mm to5.2 mm). Grip cement (DENTSPLY)
was used to anchor the guide cannula and ferrule-capped fibers to the skull.
Dummycannulae (PlasticsOne)were inserted tokeep thefiberguide fromgetting
clogged.After surgery,micewereallowed17–42days for recoveryand transgene
expression. Bilateral intracranial injections were 50–100 nl/side. To determine
dose response relationships for each injection site, wemade repeated injections
of CNO (0.3–300 mM) for each animal, separated by 2–3 days between trials.
In Vivo Photostimulation and Behavior
Components for food consumption monitoring and photostimulation were
similar to those reported previously (Aponte et al., 2011). Light was
delivered to the brain through an optical fiber (200-mm-diameter core;
BFH48-200-Multimode, NA 0.48; Thorlabs) capped with 1.25 mm OD zirco-
nia ferrules, implanted into the brain, and affixed to the skull of the animal
with dental cement. For light delivery, the implanted ferrule-capped fiber
was coupled to another optical fiber running to the fiber port with a matching
1.25 mm OD zirconium ferrule using a zirconium sleeve. The fiber tip was
positioned to a distance of 0.3 mm from the targeted region. For optical de-
livery of light pulses with millisecond precision to multiple mice, the output
from a diode laser (473 nm, Altechna) was split into four beams using
beam splitters (Fiber Sense and Signals). The main output beam from the806 Neuron 82, 797–808, May 21, 2014 ª2014 Elsevier Inc.diode laser was controlled using an acousto-optic modulator (Quanta
Tech, OPTO-ELECTRONIC) to generate light pulses that were launched
into separate fiber ports (Thorlabs) and their corresponding optical fibers.
For all in vivo photostimulation experiments, the pulse protocol was 10 ms
pulses, 20 pulses for 1 s, repeated every 4 s for 1 hr. The light power exiting
the fiber tip was 10–15 mW. Mice were allowed ad libitum access to food
overnight and, in the morning, were subjected to either 1 hr of photostimula-
tion or injection with CNO. Reported food consumption amounts are totals
over 1 hr.
Pharmacology
CNO (Enzo Life Sciences) and CNQX (20 mM; Sigma) were bath applied in
aCSF with gravity perfusion. For cerebral microinjections, CNO was diluted
in buffered saline containing 150 mMNaCl, 10 mMD-glucose, 10 mMHEPES,
2.5 mM KCl, 1 mMMgCl2 (pH 7.35), 312 mOsm. Ondansetron HCl (0.6 mg/ml;
Sigma) was dissolved in saline (Wu et al., 2012).
Electrophysiology
For details of ex vivo electrophysiology, see Supplemental Experimental
Procedures.
Ex Vivo Circuit Mapping
For brain slice optogenetic experiments, we used laser-scanning photostimu-
lation in which a laser (473 nm) was used to deliver a light as a focused spot
(0.1–1 mW) to discrete positions on the specimen (Atasoy et al., 2008). Laser
power was monitored with a photodiode. Light pulse duration (1–10 ms) was
controlled by a Pockels cell and a mechanical shutter. A focused spot of light
was targeted onto the specimen with two scanning mirrors through 43 or 633
objectives. Using a 43 objective, the light spot was moved along an 8 3 16
grid of photostimulation sites separated by 75 mm overlaid on the field of
view (Petreanu et al., 2007), perpendicular to the cortical layers in cortical re-
cordings or parallel to the third ventricle in hypothalamic recordings (Atasoy
et al., 2008; Sternson et al., 2005). To assess how hM4D would influence
action potential initiation, we made loose-seal cell-attached recordings (seal
resistance, 20–100 MU, electrode resistance 4–8 MU, aCSF internal, voltage
clamp) from transfected neurons in L2/3 or ARC. The average action potential
response fidelity (action potentials/photostimulus) from the four photostimula-
tion sites nearest the recorded cell was quantified before and during CNO
perfusion. To assess orthodromic action potential propagation, we made
axon-attached recordings (Atasoy et al., 2012) from the cut ends of L2/3
neuron transfected axons (identified by EGFP fluorescence) in layer 4 or layer
5. The average action potential fidelity was recorded in these axons during
photostimulation of four sites in the center of L2/3 before and during CNO
perfusion. For action potential backpropagation, loose-seal cell-attached re-
cordings were made from transfected L2/3 cells, and the average action po-
tential fidelity from photostimulation sites targeted to L5 was recorded before
and during CNO perfusion. To assess light-evoked synaptic transmission in
cortical slices, we made whole-cell voltage-clamp recordings from L5 neu-
rons. Measurements of L5 synaptic charge and peak amplitude were drawn
from a 4 3 4 or 5 3 5 set of photostimulation sites located in layer 2/3 and
paired-pulse values were drawn from four sites in the center of this area.
For synaptic analysis, peak amplitude is reported for simplicity, whereas sta-
tistical analysis was performed using synaptic charge transfer to account for
possible changes in ChR2-evoked spike timing induced by hM4D-mediated
hyperpolarization. Findings of statistical significance were not different be-
tween methods.
Hippocampal Neuronal Culture and Electroporation
To localize hM4D receptor present on the cell surface, we altered a tagged
hM4D construct that expresses HA at the extracellular N terminus
(HA-hM4D, Addgene ID 45548 [Armbruster et al., 2007]), by adding the
C-terminal intracellular domain of neurexin-1a (aa 1,425–1,479, codon opti-
mized, DNA 2.0) to the C terminus of HA-hM4D to produce HA-hM4Dnrxn.
Cells were transfected with HA-hM4D or HA-hM4Dnrxn DNA plus EGFP
using the Nucleofector kit (LONZA) and AMAXA electroporation unit. For de-
tails about hippocampal neuronal culture, see Supplemental Experimental
Procedures.
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After mice were used for behavioral experiments, they were transcardially
perfused with 4% paraformaldehyde (PFA) 0.1 M phosphate buffer fixative.
Tissue was postfixed in this solution for 4–12 hr and washed overnight in
PBS (pH 7.4). Brain sections (50 mm) were processed for immunohisto-
chemistry and mounted using VECTASHIELD. Microinjection experiments
were confirmed by post hoc examination of the injection site with 100 nl of
FluoroGold (Santa Cruz). Antibodies included anti-AGRP (1:5,000, goat,
Neuronomics), anti-HA (1:3,000, rat, Roche), anti-tdTomato (1:20,000, guinea
pig, Covance), and anti-EGFP (1:2,000, sheep, ABDSerotec). Fluorophore-
conjugated secondary antibodies were from Jackson ImmunoResearch
(1:500). Antibodies were diluted in PBS, 1% BSA, 0.1% Triton X-100.
For surface labeling, we used an anti-HA primary antibody, without perme-
abilization, in hippocampal neurons expressing HA-hM4D and HA-hM4Dnrxn.
Neuronal cultures (6–20 DIV, 50,000 cells per dish) transfected with 0.5 ng
EGFP and HA-hM4D or HA-hM4Dnrxn were fixed for 5 min in 4% PFA 4%
sucrose in PBS, blocked with 3% normal goat serum for 30 min, incubated
15 min with anti-HA primary (1:3,000), 60 min with Alexa 594 secondary
(1:500 in PBS), and mounted with Prolong Gold (Life Technologies). Images
were collected by confocal microscopy (Zeiss 510, Zeiss 710, and Nikon
A1R), using identical imaging conditions for both constructs. From the cell
body of transfected neurons, the EGFP-labeled axonwas followed until synap-
tic boutons could be identified. Soma:axon ratios (S/A) for hM4D and hM4Dnrxn
were quantified using ImageJ. The average somatic HA-immunofluorescence
intensity (minus average background intensity) was quantified from a single
confocal plane by centering two orthogonal linescan cross-sections across
the cell body of the surface-labeled neuron. To calculate S/A ratio, we
compared the average pixel intensity from a 0.7-mm-wide region across the
somatic cell membranes to the average HA-immunofluorescence intensity in
the axon of the same neuron, quantified from four linescans across axonal
boutons. As a negative control, cells transfected with EGFP alone were surface
immunostained for HA.
Statistics
Values are represented as means ± SEM. p values for pairwise comparisons
were calculated by Student’s t test. IC50 calculation was in MATLAB. n.s.
p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.ACCESSION NUMBERS
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